查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1858090

胃輕癱治療市場按產品類型、藥物類別、給藥途徑、分銷管道和最終用戶分類 - 全球預測 2025-2032

Gastroparesis Drugs Market by Product Type, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，胃輕癱藥物市場規模將達到 79.7 億美元，複合年成長率為 7.30%。

關鍵市場統計數據
基準年 2024 45.4億美元
預計年份：2025年 48.7億美元
預測年份 2032 79.7億美元
複合年成長率 (%) 7.30%

本書對胃輕癱的臨床複雜性、治療限制以及影響治療格局的商業性因素進行了精準而權威的介紹。

胃輕癱治療領域的特點是臨床表現複雜，患者需求尚未被滿足，且藥物治療方法既有傳統療法也有新興療法。患者症狀差異很大，現有藥物難以有效應對，臨床醫師需要在長期治療過程中權衡療效、安全性和耐受性。在此背景下，產業參與者面臨著監管審查、成本壓力以及證明病患報告結局顯著改善的挑戰。

本報告簡明扼要地說明了影響胃輕癱藥物的臨床和商業性環境。報告檢驗了藥物類別、給藥方式、通路以及最終用戶因素如何影響醫院、診所和居家醫療的用藥。透過整合最新的臨床證據、供應鏈和政策趨勢，引言部分為後續的詳細分析奠定了基礎，使決策者能夠在更廣泛的治療和營運框架內做出戰術性選擇。

對影響胃輕癱治療和商業化策略的科學、監管和商業性變革進行簡要概述

近年來，胃輕癱的治療模式發生了顯著變化，這主要得益於藥物研發趨勢、以患者為中心的監管環境以及新型給藥技術的成熟。製藥公司越來越重視針對特定機制路徑以改善胃動力並減輕全身副作用的分子。同時，口服生物製藥技術和經皮給藥概念的成熟也拓寬了臨床醫師可用的藥物套件，使其能夠提供超越簡單療效聲明的差異化提案主張。

在商業性，製藥業正經歷專科藥物研發商、契約製造和學名藥生產商之間的策略整合。這加速了現有藥物的生命週期管理策略，透過重新配方和新的給藥途徑來延長其臨床效用。同時，支付方和醫療服務提供方正轉向基於價值的合約和基於結果的報銷模式，提高了證據生成和長期安全性監測的標準。這些因素共同作用，正在重塑打入市場策略、臨床試驗設計和商業化路徑，並將繼續影響整個行業的投資重點和合作模式。

對 2025 年美國關稅上調如何加劇胃輕癱治療藥物供應鏈網路中的供應鏈、採購和定價動態進行分析性回顧。

美國高額關稅的實施，為全球原料藥供應鏈和籌資策略帶來了額外的限制和複雜性，尤其對於那些依賴進口原料藥和成品藥的藥品而言更是如此。過去透過跨境原料藥採購最佳化成本的生產網路，如今不得不重新評估供應商合格、緩衝庫存策略以及近岸外包的可行性，以緩解關稅造成的成本波動。同時，各公司也正在調整與研發和製造外包的合約條款，以分擔或承擔增加的成本負擔。

在營運方面，不斷上漲的進口關稅促使醫院藥房、專科藥品經銷商和零售通路重新審視庫存策略，許多機構延長前置作業時間並實現供應商多元化，以確保供應的連續性。臨床醫生和採購負責人可能會面臨短期價格壓力，這會影響處方模式，尤其是在存在多種治療方案的情況下。此外，關稅主導的成本上漲可能會限制製造商為後期臨床試驗和配方改良舉措提供資金的靈活性，因為資金需要重新分配以確保生產和合規性。最終，這些累積效應將凸顯增強韌性的措施的重要性，例如投資區域生產、建立策略性原料藥儲備以及加強品質監管，以在日益加強保護主義的環境下維持產品的供應和患者的用藥便利。

多維度的細分視角揭示了產品類型、治療層級、給藥途徑、管道和最終用戶如何以獨特的方式影響臨床應用和商業策略。

細分市場分析揭示了產品類型、藥物類別、給藥途徑、分銷管道和最終用戶等方面的差異化動態，這些因素共同影響治療方法的採納和商業性化進程。根據產品類型，可區分品牌學名藥。品牌藥通常以針對性的臨床數據和生命週期延長策略為支撐，而學名藥則更注重成本效益和處方滲透率。這些截然不同的動態為生產商帶來了不同的獎勵：品牌藥開發商優先考慮差異化和證據深度，而學名藥學名藥則更注重生產規模和通路最佳化。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 新型Ghrelin受體促效劑的應用日益增多，這些激動劑可改善難治性胃輕癱患者的胃動力
  • 非侵入性胃電刺激設備在門診治療糖尿病胃輕癱症狀的新應用
  • 開發甲氧氯普胺緩釋製劑，以最大限度地減少長期治療期間對中樞神經系統的副作用。
  • 增加針對多種受體路徑口服小分子促動力藥物的投資，以克服現有療法的局限性
  • 整合來自病患登記的真實世界證據，以支持高成本胃輕癱生物製藥的報銷。
  • 擴大管線研究，評估促效劑和胃動素類似物聯合治療的協同促動力作用

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的胃輕癱治療市場

  • 品牌
  • 學名藥

9. 胃輕癱藥物市場（依藥物類別分類）

  • 多巴胺拮抗劑
    • 西沙必利
    • 多潘立酮
    • 甲氧氯普胺
  • 胃動素受體促效劑
    • 阿奇黴素
    • 紅黴素
  • 血清素受體促效劑
    • Granisetron
    • Ondansetron

10. 依給藥途徑分類的胃輕癱藥物市場

  • 注射
  • 口服
  • 經皮

第11章 胃輕癱藥物市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 胃輕癱治療市場（依最終用戶分類）

  • 診所
  • 居家照護
  • 醫院

13. 各地區胃輕癱藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 胃輕癱藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國胃輕癱藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Sandoz International GmbH
    • Sun Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Johnson & Johnson
    • AbbVie Inc.
    • Ironwood Pharmaceuticals, Inc.
    • Motus GI Holdings, Inc.
    • Pfizer Inc.
Product Code: MRR-C002B1C996F5

The Gastroparesis Drugs Market is projected to grow by USD 7.97 billion at a CAGR of 7.30% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.54 billion
Estimated Year [2025] USD 4.87 billion
Forecast Year [2032] USD 7.97 billion
CAGR (%) 7.30%

A precise and authoritative introduction framing clinical complexity, treatment limitations, and commercial considerations shaping the gastroparesis therapeutic landscape

The therapeutic arena for gastroparesis is characterized by persistent clinical complexity, unmet patient needs, and a mix of legacy and evolving pharmacologic approaches. Patients experience a broad spectrum of symptoms that can be difficult to manage with existing options, while clinicians balance efficacy, safety, and tolerability in long-term care pathways. Against this backdrop, industry players are navigating regulatory scrutiny, cost pressures, and the imperative to demonstrate meaningful improvements in patient-reported outcomes.

This report provides a concise orientation to the clinical and commercial context shaping gastroparesis drugs. It examines drug class dynamics, delivery modalities, distribution pathways, and end-user considerations that influence adoption in inpatient, clinic, and home care settings. By integrating recent clinical evidence with supply chain and policy developments, the introduction sets the stage for deeper analyses that follow, enabling leaders to contextualize tactical choices within a broader therapeutic and operational framework.

A concise synthesis of the transformative scientific, regulatory, and commercial shifts reshaping gastroparesis therapeutics and commercialization strategies

Recent years have seen transformative shifts in the gastroparesis landscape driven by advances in drug development, regulatory focus on patient-centered endpoints, and the maturation of alternative delivery technologies. Pharmaceutical innovators are increasingly prioritizing molecules that target specific mechanistic pathways to improve gastric motility while mitigating systemic adverse effects. Concurrently, the maturation of oral-biologic formulation techniques and transdermal delivery concepts has broadened the pharmacologic toolkit available to clinicians, enabling differentiated value propositions beyond simple efficacy claims.

Commercially, the industry is experiencing strategic convergence between specialty developers, contract manufacturers, and generic producers. This has accelerated lifecycle management strategies for established agents through reformulation and new routes of administration that extend clinical utility. At the same time, payers and providers are shifting toward value-based contracting and outcome-aligned reimbursement, raising the bar for evidence generation and long-term safety monitoring. These combined forces are reshaping market entry strategies, clinical trial design, and commercialization pathways, and they will continue to influence investment priorities and partnership models across the sector.

An analytical review of how elevated U.S. tariffs in 2025 have amplified supply chain, procurement, and pricing dynamics across gastroparesis drug supply networks

The imposition of elevated tariffs in the United States has introduced a conditional layer of complexity into global pharmaceutical supply chains and procurement strategies, particularly for agents reliant on imported active pharmaceutical ingredients and finished dosage forms. Manufacturing networks that previously optimized cost through cross-border API sourcing must now re-evaluate supplier qualification, buffer inventory policies, and nearshoring feasibility to mitigate tariff-driven cost volatility. In parallel, firms are recalibrating contractual terms with contract development and manufacturing organizations to share or absorb incremental cost burdens, which in turn affects pricing negotiations with distributors and downstream payers.

Operationally, increased import levies have prompted a reassessment of inventory strategies for hospital pharmacies, specialty distributors, and retail channels, with many organizations extending lead times and diversifying supplier bases to protect continuity of supply. Clinicians and procurement officers may experience short-term pricing pressure that influences prescribing patterns, particularly where multiple therapeutic alternatives exist. Furthermore, tariff-driven cost increases can constrain manufacturers' flexibility to finance late-stage clinical programs or reformulation initiatives, as capital is reallocated toward ensuring uninterrupted production and compliance. Ultimately, the cumulative impact emphasizes resilience-building measures-regional manufacturing investments, strategic API stockpiles, and tightened quality oversight-to maintain product availability and preserve patient access in an increasingly protectionist trade environment.

A multi-dimensional segmentation lens revealing how product types, therapeutic classes, delivery routes, channels, and end users uniquely influence clinical adoption and commercial strategy

Segmentation analysis reveals differentiated dynamics across product type, drug class, route of administration, distribution channel, and end user that collectively shape therapeutic adoption and commercial execution. Based on Product Type, the landscape distinguishes branded therapies from generics, with branded agents typically anchored by targeted clinical data and lifecycle-extension strategies while generics emphasize cost-efficiency and formulary penetration. These opposing dynamics create distinct incentives for manufacturers: branded developers prioritize differentiation and evidence depth, whereas generic producers focus on manufacturing scale and channel optimization.

Based on Drug Class, the market is studied across Dopamine Antagonists, Motilin Receptor Agonists, and Serotonin Receptor Agonists. The Dopamine Antagonists is further studied across Cisapride, Domperidone, and Metoclopramide, where safety profiles and regulatory legacies govern prescribing limitations and monitoring requirements. The Motilin Receptor Agonists is further studied across Azithromycin and Erythromycin, which offer prokinetic properties but raise concerns about antimicrobial stewardship and long-term tolerability. The Serotonin Receptor Agonists is further studied across Granisetron and Ondansetron, which are primarily utilized for symptom control in specific care settings and may be repurposed or reformulated to enhance delivery. Differentiation across these classes is shaped not only by mechanism of action but also by demonstrable effects on patient-relevant endpoints, regulatory labeling, and long-term safety evidence.

Based on Route Of Administration, the market is studied across Injectable, Oral, and Transdermal approaches, each presenting distinct development and commercialization considerations. Injectable options can offer rapid onset and consistent pharmacokinetics but require clinical settings for administration and introduce cold-chain and device complexities. Oral formulations remain the most practicable for chronic outpatient management, yet they face bioavailability and tolerability constraints that drive reformulation efforts. Transdermal delivery presents an avenue for steady-state exposure and improved adherence but requires investment in device compatibility and robust skin tolerability data.

Based on Distribution Channel, the market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, and channel selection influences reimbursement complexity, patient access pathways, and the economics of specialty versus commodity products. Hospital pharmacies often manage inpatient and acute therapeutic needs and may drive early adoption of novel therapies supported by hospital formularies and therapeutic committees. Online pharmacies have emerged as critical access points for chronic management, where convenience and continuity of supply are weighed against regulatory controls and quality assurance. Retail pharmacies remain central to community-based dispensing and play a pivotal role in patient counseling and adherence support.

Based on End User, the market is studied across Clinics, Home Care Settings, and Hospitals, each shaping the clinical use case and service model for gastroparesis therapies. Clinics frequently manage ambulatory patients requiring ongoing symptomatic management and titration, whereas home care settings demand simplified administration, adherence-support solutions, and remote monitoring capabilities. Hospitals manage acute presentations and complex comorbidities and often influence adoption through institutional protocols and multidisciplinary care pathways. Understanding these segmentation layers helps stakeholders align clinical evidence, pricing strategies, and distribution mechanisms to the distinct needs of each subgroup, thereby informing targeted development and commercialization plans.

A strategic regional analysis illuminating how Americas, Europe, Middle East & Africa, and Asia-Pacific differences impact access, regulation, and commercialization of gastroparesis treatments

Regional dynamics exert a pronounced influence on access pathways, regulatory expectations, and commercial models across the gastroparesis space. In the Americas, incentives for innovation coexist with intense payer scrutiny and diverse reimbursement landscapes that drive differentiated go-to-market tactics and value demonstration requirements. Clinical practice variation across the Americas also shapes formulary selection and the relative uptake of novel versus established agents, while supply chain resilience remains a central operational priority.

In Europe, Middle East & Africa, fragmented regulatory frameworks and heterogeneous payer systems necessitate adaptive market entry strategies that account for localized pricing negotiations, health technology assessment processes, and varying levels of specialist availability. Countries within this expansive region may prioritize different evidence standards or access pathways, creating opportunities for targeted demonstration projects and early-access agreements. In Asia-Pacific, dynamic growth in healthcare infrastructure, expanding specialty care capacity, and rising patient awareness combine to present both opportunity and complexity. Policymakers and providers in Asia-Pacific are increasingly receptive to models that enhance outpatient management and remote-care delivery, which supports the adoption of oral and transdermal innovations. Across all regions, strategic emphasis on supply chain redundancy, regulatory alignment, and evidence generation tailored to local decision-making frameworks is essential for sustained success.

An incisive corporate overview describing how innovation, alliances, and operational resilience are redefining competitive strategies among gastroparesis drug developers

Company-level behavior in the gastroparesis domain reflects a balance between innovation, lifecycle management, and operational efficiency. Innovator firms continue to invest in targeted mechanisms that promise improved efficacy or tolerability, often coupling clinical development with biomarker strategies and patient-reported outcome measures to substantiate differentiated value. At the same time, specialty and generics manufacturers deploy cost and supply advantages to capture clinical segments where established products remain clinically acceptable.

Strategic alliances-spanning licensing, codevelopment, and contract manufacturing-have become common as firms seek to accelerate time-to-market while controlling development cost and complexity. Firms with integrated manufacturing footprints or strong partnerships with contract organizations are better positioned to absorb trade-related disruptions or to pursue regional production. Additionally, companies are increasingly investing in digital therapeutics adjuncts, remote monitoring, and adherence platforms that complement pharmacologic therapy and provide richer real-world evidence. Collectively, these company-level strategies indicate a pragmatic shift toward collaborative, patient-focused, and operationally resilient business models that sustain long-term competitive advantage.

Practical and prioritized recommendations for industry leaders to strengthen evidence generation, supply resilience, and value-based adoption for gastroparesis therapies

Leaders seeking to secure advantage in gastroparesis therapeutics should prioritize evidence frameworks that demonstrate patient-centered outcomes and real-world effectiveness. Early investment in patient-reported outcome measures, long-term safety registries, and pragmatic trial designs will strengthen value propositions for payers and providers and support differentiated positioning versus incumbent therapies. Strategic collaboration with clinicians and patient advocacy networks can accelerate meaningful endpoint selection and uptake while enriching post-launch data capture.

Operationally, companies should diversify supply chains and evaluate selective nearshoring or regional manufacturing options to mitigate tariff sensitivity and procurement disruption. Investing in digital adherence tools and companion care models will increase the stickiness of therapies delivered in home care and outpatient settings, and these adjuncts can be leveraged to generate ongoing real-world evidence. Finally, pricing strategies must be aligned with demonstrated clinical value, with alternative contracting models considered where outcomes can be reliably measured and validated. Taken together, these measures enable firms to balance access, affordability, and innovation in a rapidly evolving therapeutic and policy landscape.

A transparent and rigorous methodological summary describing how secondary research and targeted primary interviews were triangulated to produce validated insights for stakeholders

The research methodology underpinning this analysis combined systematic secondary research with targeted primary data collection to ensure both breadth and depth of evidence. Secondary sources included peer-reviewed clinical literature, regulatory guidance documents, and publicly available corporate disclosures, which were synthesized to map therapeutic mechanisms, safety profiles, and regulatory precedents. This foundation was augmented by primary interviews with clinical specialists, supply chain executives, and reimbursement experts to capture real-time perspectives on access barriers, prescribing behavior, and procurement dynamics.

Data synthesis followed a triangulation process to reconcile divergent perspectives and to validate trends across independent sources. Qualitative insights were coded thematically to identify recurring strategic imperatives and operational constraints, while cross-regional comparisons highlighted contextual differences relevant to market entry and commercialization. Limitations include variability in regional data transparency and the evolving nature of trade policy and clinical evidence, which were explicitly accounted for through sensitivity checks and stakeholder validation sessions. The methodology thus balances rigor and pragmatism, delivering actionable intelligence grounded in multi-stakeholder evidence.

A clear and strategic conclusion that synthesizes clinical promise, commercial imperatives, and operational resilience required for successful gastroparesis program execution

In sum, the gastroparesis therapeutic environment is at an inflection point where scientific progress, policy shifts, and operational realities converge to redefine value creation. Advances in targeted pharmacology and delivery technologies offer genuine promise for improved patient outcomes, yet clinical adoption will depend on compelling evidence, payer alignment, and practical administration models that meet the needs of ambulatory and home care settings. Simultaneously, macro-level pressures such as tariffs and supply chain fragility underscore the importance of resilience and strategic sourcing in maintaining patient access and commercial viability.

The path forward requires integrated strategies that couple robust evidence generation with pragmatic operational planning. Firms that align clinical differentiation with resilient manufacturing, flexible distribution models, and outcome-focused contracting will be best positioned to create sustainable impact for patients and stakeholders alike. The insights compiled here provide a strategic foundation for leaders to refine development priorities, optimize commercial paths, and mitigate policy and supply risks as they pursue durable therapeutic and business outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of novel ghrelin receptor agonists demonstrating improved gastric motility in refractory gastroparesis patients
  • 5.2. Emerging use of noninvasive gastric electrical stimulation devices for outpatient management of diabetic gastroparesis symptoms
  • 5.3. Advancements in formulation of sustained release metoclopramide to minimize central nervous system side effects in long term therapy
  • 5.4. Rising investment in oral small molecule prokinetics targeting multiple receptor pathways to overcome current therapeutic limitations
  • 5.5. Integration of real world evidence from patient registries to support reimbursement of high cost gastroparesis biologic therapies
  • 5.6. Expansion of pipeline trials assessing combination therapies of serotonergic and motilin analogs for synergistic prokinetic effects

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastroparesis Drugs Market, by Product Type

  • 8.1. Branded
  • 8.2. Generics

9. Gastroparesis Drugs Market, by Drug Class

  • 9.1. Dopamine Antagonists
    • 9.1.1. Cisapride
    • 9.1.2. Domperidone
    • 9.1.3. Metoclopramide
  • 9.2. Motilin Receptor Agonists
    • 9.2.1. Azithromycin
    • 9.2.2. Erythromycin
  • 9.3. Serotonin Receptor Agonists
    • 9.3.1. Granisetron
    • 9.3.2. Ondansetron

10. Gastroparesis Drugs Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Transdermal

11. Gastroparesis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Gastroparesis Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care Settings
  • 12.3. Hospitals

13. Gastroparesis Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gastroparesis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gastroparesis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Teva Pharmaceutical Industries Ltd.
    • 16.3.2. Viatris Inc.
    • 16.3.3. Sandoz International GmbH
    • 16.3.4. Sun Pharmaceutical Industries Ltd.
    • 16.3.5. Dr. Reddy's Laboratories Ltd.
    • 16.3.6. Johnson & Johnson
    • 16.3.7. AbbVie Inc.
    • 16.3.8. Ironwood Pharmaceuticals, Inc.
    • 16.3.9. Motus GI Holdings, Inc.
    • 16.3.10. Pfizer Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GASTROPARESIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. GCC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GCC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. GCC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. GCC GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
  • TABLE 320. GCC GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2032 (USD MILLION)
  • TABLE 321. GCC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
  • TABLE 322. GCC GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2032 (USD MILLION)
  • TABLE 323. GCC GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION